Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376488 | 0.89 | MAOA (0.56) | HSD17B10CASP1CASP7HSD17B1MIF | |
| SCHEMBL20055113 | 0.86 | LMNA (0.52) | HSD17B10MIFLMNAMAOBMAOA | |
| SCHEMBL31137714 | 0.85 | CASP1 (0.53) | HSD17B10CASP1CASP7HSD17B1MIF | |
| SCHEMBL8599617 | 0.85 | PBRM1 (0.53) | HSD17B10CASP1CASP7HSD17B1MIF | |
| SCHEMBL16548209 | 0.82 | MCL1 (0.55) | HSD17B10CASP1CASP7HSD17B1MIF | |
| SCHEMBL7496441 | 0.79 | MIF (0.48) | HSD17B10MIFLMNAMAOBMAOA | |
| SCHEMBL25700399 | 0.77 | KDM4E (0.38) | HSD17B10CASP1CASP7HSD17B1MIF | |
| SCHEMBL8002224 | 0.77 | CASP1 (0.42) | HSD17B10CASP1CASP7HSD17B1MIF | |
| SCHEMBL12545876 | 0.77 | LMNA (0.48) | HSD17B10MIFLMNAMAOBMAOA | |
| SCHEMBL30540268 | 0.76 | MAOA (0.49) | HSD17B10MIFLMNAMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382863-A1 | MEK INHIBITORS AND USES THEREOF | IMAGENEBIO, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023208151-A1 | USP INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 北京华森英诺生物科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116621778-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| CN-1835924-A | Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor | ABBOTT LAB (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-0856514-B1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-13 | — | — | EP | disclosed |
| US-6071925-A | ANTIDEPRESSANTS, ANTICONVULSANTS OR ANTIANXIETY AGENTS, ALSO FOR TREATMENT OF MEMORY LOSS IN ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0856514-A1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-08-05 | — | — | EP | disclosed |
| US-3954983-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS | RICHARDSON-MERRELL INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | HSD17B10 1566/4885CASP1 2005/4885CASP7 732/4885 |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | HSD17B10 2237/4885CASP1 1237/4885CASP7 2166/4885 |
| US-20230382863-A1 | MEK INHIBITORS AND USES THEREOF | BRAF, NRAS, KRAS | HSD17B10 3255/4885CASP1 2578/4885CASP7 1487/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | HSD17B10 3340/4885CASP1 3621/4885CASP7 2891/4885 |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HSD17B10 1605/4885CASP1 3384/4885CASP7 3455/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | HSD17B10 2652/4885CASP1 678/4885CASP7 2692/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | HSD17B10 135/4885CASP1 1683/4885CASP7 2400/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | HSD17B10 2245/4885CASP1 3342/4885CASP7 2182/4885 |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | BRD4, BRD3, BRD1 | HSD17B10 1605/4885CASP1 3384/4885CASP7 3455/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | HSD17B10 2659/4885CASP1 474/4885CASP7 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.